The Alderley Park Discovery Podcast: COVID testing and the Lighthouse LabAlderley Park’s Mereside campus is at the forefront of the UK’s COVID-19 testing plans, playing a key role Share XThe Alderley Park Discovery Podcast: COVID testing and the Lighthouse Labhttps://pharmaphorum.com/podcast/alderley-park-discovery-podcast-lighthouse-lab/
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcastAlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing Share XAlnylam, gene-silencing and biotech in 2020: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/alnylam-gene-silencing-biotech-2020/
Investing in innovation – new digital approaches for a new decade For the first time in history, we have the technologies that will allow us to develop new Share XInvesting in innovation – new digital approaches for a new decadehttps://pharmaphorum.com/views-analysis-digital/investing-in-innovation-new-digital-approaches-for-a-new-decade/
Sanofi’s Bozidar Jovicevic on how the company is approaching digital therapeuticsPaul Tunnah caught up with Sanofi’s vice president, global head of digital therapeutics at JP Morgan to talk Share XSanofi’s Bozidar Jovicevic on how the company is approaching digital therapeuticshttps://pharmaphorum.com/video/sanofis-bozidar-jovicevic-on-how-the-company-is-approaching-digital-therapeutics/
UCB’s James Musick on embracing digital therapeuticsDigital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it. Share XUCB’s James Musick on embracing digital therapeuticshttps://pharmaphorum.com/views-analysis-digital/ucbs-james-musick-on-embracing-digital-therapeutics/
Millendo’s Julia Owens on leadership in rare diseasesRare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome. Share XMillendo’s Julia Owens on leadership in rare diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/millendo-julia-owens-leadership-rare-diseases/
Helsinn’s Riccardo Braglia on the patient perspective in cancer careSwiss cancer care company Helsinn has become unique in the industry by remaining a family business over three Share XHelsinn’s Riccardo Braglia on the patient perspective in cancer carehttps://pharmaphorum.com/views-analysis-oncology/helsinns-riccardo-braglia-patient-perspective-cancer-care/
Leading from the front in cell therapyIn these videos, senior stakeholders from Kite, a Gilead Company, describe how a culture of innovation and partnership Share XLeading from the front in cell therapyhttps://pharmaphorum.com/video/leading-from-the-front-in-cell-therapy/
Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
